En estos ensayos, Ozempic ha proporcionado una mayor reduccin de los niveles de glucosa en sangre (HbA1c) y del peso corporal en comparacin con otros tratamientos para la diabetes tipo 2 (sitagliptina, exenatida de liberacin prolongada, insulina glargina U100 y dulaglutida)[5-8], adems de demostrar beneficios cardiovasculares y una reduccin estadsticamente significativa de la aparicin o progresin de la nefropata diabtica frente a placebo conjuntamente con el tratamiento estndar[4]
The best available data show that both semaglutide and tirzepatide reduce fat mass substantially and lean mass to a lesser extent, roughly in proportion to total weight lost
It was demonstrated that the altered human microbiota due to the surgery reduced fat deposition in the germ-free recipient mice colonized with bacteria from stool samples from the human donors (95)
#3 Orforglipron in Type 2 Diabetes: ACHIEVE-1 Trial Orforglipron is structurally distinct, as a non-peptide, small-molecule GLP-1 receptor agonist
Chang CF, Massey J, Osherov A, Angenendt da Costa LH, Sansing LH